Compound ID | 399
NZ2114
Class: Antimicrobial peptide (plectasin derived)
| Spectrum of activity: | Gram-negative |
| Details of activity: | Cell wall inhibitor; was in preclinical trials with Sanofi Aventis for Gram positive infections. This demonstrated good tolerance in animal trials |
| Description: | 1. Nielsen LA, Ravn BT, Lichtenberg J, et al. In vivo profiling of plectasin variant NZ2114, a novel promising antimicrobial peptide. 47th-ICAAC-2007 2007;243 2. Sandvang D, Mygind PH, Jones ME, et al. In vitro activity and characterization of NZ2114: an improved variant of plectasin. 47th-ICAAC-2007 2007;243 |
| Institute where first reported: | Novozymes A/S, Denmark; Sanofi Aventis, France |
| Year first mentioned: | 2007 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| External links: | |
| Citation: | https://journals.asm.org/doi/10.1128/aac.00685-09 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.